The New Drug Reimbursement Game: A Regulator’s Guide to Playing and Winning 2015th Edition
“I like this book … and would recommend it to anyone who wishes to understand the negotiations between health-care payers and biopharmaceutical companies. … Pekarsky provides useful overviews of the many academic fields that contribute to debates on the appropriate price to pay for new drugs … .” (Christopher J. McCabe, Applied Health Economics and Health Policy, October, 2015)
From the Back Cover
This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure.
Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare. The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price.
The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.
DOWNLOAD THIS BOOK FREE HERE
This website strictly complies with DMCA Digital Copyright Laws..Please be clear that we (emedicalbooks.com) do not own copyrights of these e-books. The intention behind sharing these books and educational material is to provide easy access to medical students, doctors and other individuals related to the field of medical science, "thus only for educational purpose". We highly encourage our readers to purchase this content from the respected publishers. If anyone holding copyrights wants us to remove this content, please contact us rightaway. All books and educational material on emedicalbooks.com are free and NOT HOSTED ON OUR WEBSITE. If you feel that your copyrights have been violated, then please contact us immediately. You may send an email to email@example.com for all DMCA / Removal Requests. emedicalbooks.com doesn’t have any material hosted on the server of this page, only links to books that are taken from other sites on the web are published and these links are unrelated to the book server. emedicalbooks.com server doesnot store any type of book or material. No illegal copies are made or any copyright © and / or copyright is damaged or infringed since all material is free on the internet.